Nipun B Merchant
Overview
Explore the profile of Nipun B Merchant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
3701
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martos M, Lee M, Merchant N, Kobetz E, Hester C, Stathias V, et al.
Ann Surg Oncol
. 2025 Feb;
PMID: 40009307
No abstract available.
2.
Dosch A, Martos M, Singh S, Kodia K, Merchant N, Nagathihalli N
Gastro Hep Adv
. 2025 Jan;
4(1):100538.
PMID: 39790246
The development of hepatic metastases is the leading cause of mortality in gastrointestinal (GI) cancers and substantial research efforts have been focused on elucidating the intricate mechanisms by which tumor...
3.
Amirian H, Dickey E, Ogobuiro I, Box E, Shah A, Martos M, et al.
J Surg Oncol
. 2024 Aug;
130(5):1023-1032.
PMID: 39165230
Background: In patients with localized pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant therapy (NAT) and resection, selection of adjuvant chemotherapy (AC) is typically guided by high-risk features on histopathologic examination. We...
4.
Fleming A, Gehle D, Freitas J, Hendrick L, Yakoub D, Abdelhafeez H, et al.
J Surg Oncol
. 2024 Aug;
130(5):1051-1061.
PMID: 39155692
Background And Objectives: Solid pseudopapillary neoplasm (SPN) of the pancreas demonstrates an indolent disease course; however, some patients present with a "malignant" phenotype, including distant metastases resistant to chemotherapy. This...
5.
Permuth J, Park M, Chen D, Basinski T, Powers B, Gwede C, et al.
Front Oncol
. 2024 Aug;
14:1362244.
PMID: 39109281
Introduction: Cancer-associated cachexia (CC) is a progressive syndrome characterized by unintentional weight loss, muscle atrophy, fatigue, and poor outcomes that affects most patients with pancreatic ductal adenocarcinoma (PDAC). The ability...
6.
Deshpande N, Bianchi A, Amirian H, De Castro Silva I, Rafie C, Surnar B, et al.
bioRxiv
. 2024 Jun;
PMID: 38854120
Pancreatic ductal adenocarcinoma (PDAC) is characterized by intratumoral abundance of neutrophilic/polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) which inhibit T-cell function through JAK2/STAT3-regulated arginase activity. To overcome limitations of systemic inhibition of...
7.
Zogopoulos G, Haimi I, Sanoba S, Everett J, Wang Y, Katona B, et al.
J Natl Compr Canc Netw
. 2024 Apr;
22(3):158-166.
PMID: 38626807
Background: Pancreatic adenocarcinoma (PC) is a highly lethal malignancy with a survival rate of only 12%. Surveillance is recommended for high-risk individuals (HRIs), but it is not widely adopted. To...
8.
Martos M, Amirian H, Dickey E, Box E, Merchant N, Hosein P, et al.
Hepatobiliary Surg Nutr
. 2024 Apr;
13(2):325-328.
PMID: 38617473
No abstract available.
9.
Singh S, Dosch A, Mehra S, De Castro Silva I, Bianchi A, Garrido V, et al.
Cancer Res
. 2024 Jan;
84(8):1320-1332.
PMID: 38285896
Significance: Inhibition of p38 MAPK suppresses tumor cell-derived IL1α and attenuates the inflammatory stroma and immunosuppressive tumor microenvironment to overcome chemotherapeutic resistance in pancreatic cancer.
10.
Ogobuiro I, Baca Y, Ribeiro J, Walker P, Wilson G, Gulhati P, et al.
JCO Precis Oncol
. 2023 Nov;
7:e2300152.
PMID: 37944072
Purpose: Using a real-world database with matched genomic-transcriptomic molecular data, we sought to characterize the distinct molecular correlates underlying clinical differences between patients with young-onset pancreatic cancer (YOPC; younger than...